|
KMID : 0606920210290030290
|
|
Biomolecules & Therapeutics
2021 Volume.29 No. 3 p.290 ~ p.294
|
|
|
3’-O-Acetyl-24-Epi-7,8-Didehydrocimigenol-3-O-β-DXylopryranoside Decreases Amyloid Beta Production in Amyloid Precursor Protein-Transfected HeLa Cells
|
|
Lee Sang-Bin
Park An-Sun
Ma Chi Thanh
Kim Young-Ho
Yang Hyun-Ok
|
|
|
Abstract
|
|
|
|
Extracellular beta amyloid (Aβ) plaques are the neuropathological hallmarks of Alzheimer’s disease (AD). Accordingly, reducing Aβ levels is considered a promising strategy for AD prevention. 3’-O-acetyl-24-epi-7,8-didehydrocimigenol-3-O-β-D-xylopryranoside significantly decreased the Aβ production and this effect was accompanied with reduced sAPPβ production known as a soluble ectodomain APP fragment through β-secretases in HeLa cells overexpressing amyloid precursor proteins (APPs). This compound also increased the level of sAPPα, which is a proteolytic fragment of APP by α-secretases. In addition, 3’-O-acetyl-24-epi-7,8-didehydrocimigenol-3-O-β-D-xylopryranoside decreased the protein level of β-secretases, but the protein levels of A disintegrin and metalloproteinase (ADAM) family, especially ADAM10 and ADAM17, are increased. Thus, 3’-O-acetyl-24-epi-7,8-didehydrocimigenol-3-O-β-D-xylopryranoside could be useful in the development of AD treatment in the aspect of amyloid pathology.
|
|
|
KEYWORD
|
|
|
Alzheimer’s disease, Anti-amyloidogenic effect, Secretases
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|